

Halar Road Cross Lane, Besides L.I.C. Bldg. Valsad-396 001. Ph.: (02632) 243280. Mo.: 99250 49280

 ROHIT - PATIAL
 Reg. Date : 30/12/2022

 Male/28 Years
 Lab. No
 124815-18

Sample No \*5230\*

Ref. Dr.

Dr. (Mrs.) SHASHIKALA DERAJE M B B S. A.F.I.H VIBRANT HOSPITAL VAP1

#### HEMATOLOGY REPORT

	<u> </u>	LUGI	<u>KEPUKI</u>
Test	Result	Unit	Ref. Range
Haemoglobin:	13.7	g/dL	13.0 - 17.0 g/dL
<b>Total Leucocyte Count:</b>	6440	$X~10^3$ / $\mu L$	4000 - 10000 /uL
Differential Count			
Neutrophils:	49	%	40-80
Eosinophils:	02	%	1.0-6.0
Basophils:	00	%	<1-2
Lymphocytes:;	<u>43</u>	%	M: 20-40; F: 20-40
Monocytes:	06	%	2-10
Neutrophils Absolute Count:	3.12	$X~10^3$ / $\mu L$	2.0-7.0
Eosinophils Absolute Count:	0.14	$X~10^3$ / $\mu L$	0.02-0.50
Basophils Absolute Count:	0.04	$X~10^3$ / $\mu L$	0.02-0.10
Lymphocytes Absolute Count:	2.76	$X~10^3$ / $\mu L$	1.0-3.0
Monocytes Absolute Count:	0.38	$X~10^3$ / $\mu L$	0.2-1.0
Total RBC Count:	5.17	X 106 / μL	M: 4.5-5.5; F: 3.9-4.8
Hematocrit (HCT):	<u>41.6</u>	%	42 - 52 %
MCV:	80.5	fL	83 - 101
MCH:	<u> 26.5</u>	pg	27-32
MCHC:	32.9	g/dL	31.5 - 34.5
RDW-SD:	<u>43.2</u>	fL	39 - 46
RDW-CV:	13.2	%	11.6 - 14.0
Platelets Count:	182000	/µL	150000 - 400000
Plateletcrit (PCT):	0.225	%	
Mean Platelet Volume	12.3	fL	
Malaraial Parasite	M.P. are not s	seen	

Method: Fully automated bidirectional interfaced analyser (6 Part Differential SYSMEX XN-1000).

LAB USE ONLY (Enter Date/Time:30/12/2022 10:57:00 AM) ( Verify Date/Time:30/12/2022 10:57:00 AM)



 ROHIT - PATIAL
 Reg. Date : 30/12/2022

 Male/28 Years
 Lab. No 124815-18

Sample No \*5230\*

Ref. Dr.

Dr. (Mrs.) SHASHIKALA DERAJE M B B S. A.F.I.H VIBRANT HOSPITAL VAP1

# BLOOD GROUP

Test Result

BLOOD GROUP: "O"Rh.POSITIVE

LAB USE ONLY (Enter Date/Time:30/12/2022 12:53:00 PM) ( Verify Date/Time:30/12/2022 12:53:00 PM)



**ROHIT - PATIAL** Reg. Date: Male/28 Years Lab. No

Sample No

\*5230\*

Ref. Dr.

Dr. (Mrs.) SHASHIKALA DERAJE M B B S. A.F.I.H **VIBRANT HOSPITAL VAP1** 

ESR

30/12/2022

124815-18

**Test** Result Unit Ref. Range **Erythrocyte Sedimentation Rate:-**After one Hour: 80 2 - 13 mm in 1Hr. mm in 1Hr

LAB USE ONLY (Enter Date/Time:30/12/2022 3:03:00 PM) ( Verify Date/Time:30/12/2022 3:03:00 PM)



 ROHIT - PATIAL
 Reg. Date : 30/12/2022

 Male/28 Years
 Lab. No 124815-18

Sample No

\*5230\*

Ref. Dr.

Dr. (Mrs.) SHASHIKALA DERAJE M B B S. A.F.I.H VIBRANT HOSPITAL VAP1

# BLOOD GLUCOSE REPORT

Test	Result	Unit	Ref. Range
Fasting Blood Sugar(FBS) :	<u>190</u>	mg/dl	70 - 110 mg/dl

LAB USE ONLY (Enter Date/Time:30/12/2022 3:03:00 PM) ( Verify Date/Time:30/12/2022 3:03:00 PM)

 ROHIT - PATIAL
 Reg. Date : 30/12/2022

 Male/28 Years
 Lab. No 124815-18

Sample No \*5230\*

Ref. Dr.

Dr. (Mrs.) SHASHIKALA DERAJE M B B S. A.F.I.H VIBRANT HOSPITAL VAP1

### LIPID PROFILE

Test	Result	Unit	Ref. Range
S. Cholesterol:	<u>249.50</u>	mg/dL	DESIRABLE < 200 BORDERLINE HIGH 200 - 239 HIGH RISK > 240
S. Triglyceride:	167.63	mg/dL	25 - 175 mg/dL
S. HDL Cholesterol (HDL - C):	44.54	mg/dL	LOW RISK > 60 MODERATE RISK 35 - 60 HIGH RISK <35
S. LDL Cholesterol (LDL - C)	<u>171.434</u>	mg/dL	OPTIMAL <100 NEAR/ABOVE OPTIMAL 100 - 129 BORDERLINE HIGH 130 -159 HIGH RISK > 160
S. VLDL Cholesterol (VLDL - C)	33.53	mg/dL	7.0 - 35 mg/dl
Cholesterol/HDL Cholesterol Ratio: S. LDL/HDL Cholesterol Ratio:	<b>5.6</b> 3.85	5, 42	0 - 4.9 up to 3.5

#### INTERPRETATION AND DECISION LEVELS

- 1) Do Not Use Age Or Sex Specific Cholestrol Valuse As Decision Levels.
- 2) Before Starting Therapy Base <u>Ldl Levels by Direct Measurements</u> Should Be Done As The Treatment Goals Are Monitored By Measuring Ldl.
- 3) Average Of 2 To 3 Lipid Profiles Done 1 To 8 Weeks Apart Before Starting Therapy.
- 4) Ranges Give Are The Desirable Levels I.e 75th Percentile Value.
- 5) Always Rule Out Secondary And Familial Hyper Lipidaemias.
- 6) Apo A -1 And Apo B Levels Are Better Discreminaters Of CHD Then Cholestrol Level.
- 7) Low Plasma Apo A-1 And Apo A-1 To B Ratio Is The Best Predictyor.
- 8) Low Plasma **B-12 And Folate Levels** Are Each Independent Risk Factors For CAD.
- 9) Higher Atherogenic Index Is A Risk Factor.
- 10) Hyperhomocysteinemia Increases The Risk.

#### **DECISION LEVELS**

	LDL	HDL	CHOL	LDL/HDL RATIO	TRIGLYCERIDES
DESIRABLE/LOW RISK	<100	>60	<200	0.5 - 3.0	<200
BORDERLINE/MODERATE	130 - 159	35-60	200-239	3.0 - 6.0	200 - 400
ELEVATED/HIGH RISK	>160	<35	>240	>6.0	400 - 1000



 ROHIT - PATIAL
 Reg. Date : 30/12/2022

 Male/28 Years
 Lab. No 124815-18

Sample No

\*5230\*

Ref. Dr.

Dr. (Mrs.) SHASHIKALA DERAJE M B B S. A.F.I.H VIBRANT HOSPITAL VAP1



 ROHIT - PATIAL
 Reg. Date : 30/12/2022

 Male/28 Years
 Lab. No 124815-18

Sample No

\*5230\*

Ref. Dr.

Dr. (Mrs.) SHASHIKALA DERAJE M B B S. A.F.I.H VIBRANT HOSPITAL VAP1

# BIOCHEMISTRY REPORT

Test	Result	Unit	Ref. Range
SERUM BILIRUBIN Total:	0.76	mg/dL	1.0
Direct:	0.16	mg/dL	0.0 - 0.4
Indirect:	0.6	mg/dL	0.0 - 0.6 mg/dL
S.G.O.T. (AST):	<u>59.97</u>	IU/L	10 - 40 U/L
S.G.P.T. (ALT):	108.01	IU/L	10 - 40 IU/L
Alkaline Phosphatase:	<u>164.6</u>	U/L	30 - 115 U/L
S.Creatinine:	0.72	mg/dL	0.60 - 1.30 mg/dL
S.Urea:	34.46	mg/dL	15 - 40 mg/dL
S. URIC ACID:	4.68	mg/dL	2.5 - 8.0 mg/dL

LAB USE ONLY (Enter Date/Time:30/12/2022 3:05:00 PM) ( Verify Date/Time:30/12/2022 3:05:00 PM)



Halar Road Cross Lane, Besides L.I.C. Bldg. Valsad-396 001. Ph.: (02632) 243280. Mo.: 99250 49280

 ROHIT - PATIAL
 Reg. Date : 30/12/2022

 Male/28 Years
 Lab. No 124815-18

Sample No \*5230\*

Ref. Dr.

Dr. (Mrs.) SHASHIKALA DERAJE M B B S. A.F.I.H VIBRANT HOSPITAL VAP1

# SERUM TOTAL PROTEINS

Test	Result	Unit	Ref. Range
S.Protein:			
Total Protein:	7.22	gm/dl	5.5 - 8.0 g/dL
Albumin:	4.31	gm/dl	3.2 - 5.2 g/dL
Globulin:	2.91	gm/dl	2.0 - 3.5 gms/dl
Albumin Globulin Ratio:	1.48		

LAB USE ONLY (Enter Date/Time:30/12/2022 3:05:00 PM) ( Verify Date/Time:30/12/2022 3:05:00 PM)



 ROHIT - PATIAL
 Reg. Date : 30/12/2022

 Male/28 Years
 Lab. No 124815-18

Sample No \*5230\*

Ref. Dr.

Dr. (Mrs.) SHASHIKALA DERAJE M B B S. A.F.I.H VIBRANT HOSPITAL VAP1

SERUM PHOSPHORUS

Test	Result	Unit	Ref. Range
S. Phosphorus :	3.71	mg/dL	3.0 - 5.0 mg/dl

LAB USE ONLY (Enter Date/Time:30/12/2022 5:53:00 PM) ( Verify Date/Time:30/12/2022 5:53:00 PM)



 ROHIT - PATIAL
 Reg. Date : 30/12/2022

 Male/28 Years
 Lab. No 124815-18

Sample No \*5230\*

Ref. Dr.

Dr. (Mrs.) SHASHIKALA DERAJE M B B S. A.F.I.H

**VIBRANT HOSPITAL VAP1** 

# URINE REPORT

Test	Result	Unit	Ref. Range
PHYSICAL EXAMINATION			
QUANTITY	30	mL	500 - 2000/24 HRS
COLOUR APPEARANCE	PALE YELLOW Clear	Clear	
REACTION(PH)	6.0		4.6 - 8.0
SPECIFIC GRAVITY	1.025		1.005 - 1.030
CHEMICAL EXAMINATION			
URINE ALBUMIN	Nil		Absent
URINE SUGAR(Qualitative)	Present (++)		Absent
KETONES	Absent		Absent
BILE SALTS	Absent		Absent
BILE PIGMENTS	Absent		Absent
UROBILOGEN	Normal		Normal
BLOOD	Absent		Absent
MICROSCOPIC EXAMINATION			
PUS CELLS/HPF	1 - 2 / HPF	/HPF	1 - 5
RED BLOOD CELLS/HPF	Absent	/HPF	0 - 2/hpf
EPITHELIAL CELLS/HPF	2 - 3 / HPF	/HPF	
CASTS/LPF	Absent		
CRYSTALS BACTERIA YEAST NOTE REMARK	Absent ABSENT Absent		
UNE			

LAB USE ONLY (Enter Date/Time:30/12/2022 10:49:00 AM) ( Verify Date/Time:30/12/2022 3:05:00 PM)



**ROHIT - PATIAL** Reg. Date: 30/12/2022 Male/28 Years Lab. No 124815-18

Sample No

\*5230\*

Ref. Dr.

Dr. (Mrs.) SHASHIKALA DERAJE M B B S. A.F.I.H VIBRANT HOSPITAL VAP1

#### THYROID FUNCTION TEST

**Test** Result Unit Ref. Range **TSH (Thyroid Stimulating Hormone)** 5.16 uIU/mL 0.3 - 5.0 uIU/mL

#### THYROID FUNCTION TESTS BY ELECTROCHEMILUMINESCENCE (ECLIA) ON ELECSYS 2010.

- T3 And T4 Are The Hormones Synthesised & Secreted By Throid Gland, Plays Important Role In Body's metabolism.TSH Is Synthesised & Secreted By Anterior Pitutary Gland In Response To Thyrotropin Releasing Hormone (trh) Secreted By Hypothalamus. The Secretion Of T3 & T4 Is Regulated By Negative Feedback Mechanism Inolving Thyroid Gland, Pitutary gland & Hypothalamus.
- In The Circulation 99.7% Of T3 & 99.95% Of T4 Is Reversibly Bound To Transport Proteins Primarily, Thyroxine Binding Globulin (TBG) & Thyroxine Binding Prelalbumin (TBPA), are Metabolically Inactive. Free T3 & Free T4 Are Metabolically Active Hormones Responsible For The Actions Hence Reflects The Thyroid Metabolic Status Better Then Total T3 & T4.
- TBG Concentration Remains Relative Constant In Healthy Individuals.however Pregnancy, excess estrogens, androgens, anabolic Steroids & Gluco Corticodis Are Known To Alter TBG Levels & May Cause False Values For Thyroid Function TestS,T3 And T4 Levels May Not Accurately Reflect Thyroid Status.
- Primary Malfunction Of The Thyroid Gland May Result In Excessive (hyper) Or Below Normal (hypo) Release of T3 & T4.In Addition TSH Directly Effects Thyroid Function. Malfunction Of The Pitutary Or The Hypothalamus Influences The Thyroid Gland Acitvity.
- Disease In Any Portion Of The Thyroid Pitutary Hypothalamic System May Influence The Levels Of T3 & T4 In The Blood. The TSH Level Is Important In Evaluating Thyroid Function Especially For The Differential Diagnosis Of Primary (thyoid) From Secondary (pitutary) And Tertiary (hypothalamus) Hypo Thyroidism.
- In Primary Hypothyroidism TSH Levels Are Significatly Elevated, While In Secondary & Tertiary Hypothyroidism TSH Levels Are Low.In Addition In The Euthyroid Sick Syndrome Multiple Alterations In Thyroid Function Tests Findings Have Been Recognised In Patiens With A Wide Variely Of Non Thyroidal Illnesses Withouth Evidence Of Pre-existing Thyroid Or Hypothalamic Pitutary Disease.

LAB USE ONLY (Enter Date/Time:30/12/2022 5:53:00 PM) ( Verify Date/Time:30/12/2022 5:53:00 PM)



ROHIT - PATIAL Reg. Date : 30/12/2022
Male/28 Years Lab. No 124815-18

Sample No

\*5230\*

Ref. Dr.

Dr. (Mrs.) SHASHIKALA DERAJE M B B S. A.F.I.H VIBRANT HOSPITAL VAP1

#### GLYCOSYLATED HAEMOGLOBIN REPORT

Test Result Unit Ref. Range

HbA1c-GLYCOSYLATED HEMOGLOBIN A1c 9.4 % 4.8 - 6.0 %

Note

Method: DCCT/NGSP Standardised

**HPLC on BIORAD D10** 

MEAN PLASMA GLUCOSE (eAG) 223.08 mg/dL

**REFERENCE RANGE** 

NORMAL HEALTHY PEOPLE : 4.0 -6.0 % GOOD DIABETIC CONTROL : 6.0 - 7.0 % FAIR DIABETIC CONTROL : 7.0 - 8.0 % POOR DIABETIC CONTROL : MORE THEN 8%

#### **INTERPRETATION**

- \* **GLUOCSE** combines with **HEMOGLOBIN** continuously & nearly irreversibly during lifespan of **RBC** (120 days); Thus GHb will be proportional to the mean plasma glucose level during 6 12 weeks.
- \* The HbA1c levels corelate well the mean glucose concentration prevailing in the course of Patient's recent history (apprx 6-8 weeks) & therefore provides much more reliable information for glycaemia control then the blood glucose or urinary glucose.
- \* This Methodology is the REFERENCE METHODOLOGY, better then the routine chromatographic methods & also for the daibetic pts.having HEMOGLBINOPATHIES OR UREMIA as Hb varaints and uremia dose not INTERFERE with the results in this methodology.
- \* It is recommended that HbA1c levels be performed at 4 8 weeks during therapy in uncontrolled DM pts.& every 3 4 months in well controlled daibetics .
- \* Mean blood glucose (MBG) in first 30 days (0-30) before sampling for HbA1c contributes 50% whereas MBG in 90 120 days contribute 10% in final HbA1c levels

LAB USE ONLY (Enter Date/Time:30/12/2022 6:40:00 PM) ( Verify Date/Time:30/12/2022 6:40:00 PM)



 ROHIT - PATIAL
 Reg. Date : 30/12/2022

 Male/28 Years
 Lab. No 124815-18

Sample No \*5230\*

Ref. Dr.

Dr. (Mrs.) SHASHIKALA DERAJE M B B S. A.F.I.H VIBRANT HOSPITAL VAP1

# SERUM CALCIUM

Test	Result	Unit	Ref. Range
S. Calcium :	9.89	mg/dL	9.0 - 10.5 mg/dl

 $LAB\ USE\ ONLY\ (Enter\ Date/Time: 30/12/2022\ 3:06:00\ PM)\ \ (\ Verify\ Date/Time: 30/12/2022\ 3:06:00\ PM)$